Alpha 2.0
Login Register
» Articles » PMID: 16513441

Risk Assessment in Drug Development for Symptomatic Indications: a Framework for the Prospective Exclusion of Unacceptable Cardiovascular Risk

Overview
Journal Clin Pharmacol Ther
Publisher Wiley
Specialty Pharmacology
Date 2006 Mar 4
PMID 16513441
Citations 6
Authors
Eric P Brass
Roger J Lewis
Raymond Lipicky
James Murphy
William R Hiatt
Affiliations
Soon will be listed here.
Citing Articles

Leveraging Machine Learning and Artificial Intelligence to Improve Peripheral Artery Disease Detection, Treatment, and Outcomes.

Flores A, Demsas F, Leeper N, Ross E Circ Res. 2021; 128(12):1833-1850.

PMID: 34110911 PMC: 8285054. DOI: 10.1161/CIRCRESAHA.121.318224.

Drugs' development in acute heart failure: what went wrong?.

Teneggi V, Sivakumar N, Chen D, Matter A Heart Fail Rev. 2018; 23(5):667-691.

PMID: 29736812 DOI: 10.1007/s10741-018-9707-y.

The Food and Drug Administration and the Future of Drug Development for the Treatment of Diabetes.

Brass E Diabetes Spectr. 2015; 27(2):75-7.

PMID: 26246760 PMC: 4522876. DOI: 10.2337/diaspect.27.2.75.

Use of alternative methodologies for evaluation of composite end points in trials of therapies for critical limb ischemia.

Subherwal S, Anstrom K, Jones W, Felker M, Misra S, Conte M Am Heart J. 2012; 164(3):277-84.

PMID: 22980292 PMC: 3950277. DOI: 10.1016/j.ahj.2012.07.002.

International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes.

Bass A, Darpo B, Breidenbach A, Bruse K, Feldman H, Garnes D Br J Pharmacol. 2008; 154(7):1491-501.

PMID: 18663380 PMC: 2492102. DOI: 10.1038/bjp.2008.279.